Clinical research
Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.
The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo.
As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
Summit Therapeutics plc announced the presentation of new data that explain the link between two key findings in the Company’s Phase 2 clinical trial of ridinilazole for C. difficile infection
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy.
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
Target number of clinical sites reached, including leading hospitals and geriatric centers in the US and Europe Patient enrollment expected to complete in mid-2020
It was another busy week for clinical trials. Here’s a look.
PRESS RELEASES